Efficacy and Safety of Low-Dose Rituximab in Anti-MuSK Myasthenia Gravis Patients: A Retrospective Study
Xin Meng,Ziling Zeng,Yunda Wang,Shuai Guo,Chunjuan Wang,Baojie Wang,Shougang Guo
DOI: https://doi.org/10.2147/NDT.S358851
IF: 2.989
2022-05-04
Neuropsychiatric Disease and Treatment
Abstract:Xin Meng, 1 Ziling Zeng, 2 Yunda Wang, 3 Shuai Guo, 1 Chunjuan Wang, 2 Baojie Wang, 1 Shougang Guo 1, 2 1 Department of Neurology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, People's Republic of China; 2 Department of Neurology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, People's Republic of China; 3 Department of Neurosurgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, People's Republic of China Correspondence: Shougang Guo, Department of Neurology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jing Wu Road, Huaiyin District, Jinan, Shandong, 250021, People's Republic of China, Tel +86-13220585081, Fax +86-531-87937741, Email Purpose: To evaluate the efficacy and safety of low dosages of rituximab (RTX) in the treatment of MuSK-antibody-positive MG patients. Patients and Methods: We retrospectively analyzed the data of MuSK-antibody-positive MG patients who were treated with low dosages of RTX from January 2018 to October 2021. The long-term treatment response to RTX was assessed by Myasthenia Gravis Foundation of America (MGFA) post-interventional status (PIS), Myasthenia Gravis Status and Treatment Intensity (MGSTI), dosage of steroid, MG-related activities of daily living (MG-ADL) and myasthenic muscle score (MMS) at the end of follow-up. Results: Clinical improvement was observed in all eight patients with follow-up for 8 to 29 months after treatment. At the last visit, complete stable remission had been achieved in one patient, pharmacologic remission in three patients, minimal manifestations status in three patients and improved in one patient based on the MGFA-PIS criteria. MGSTI level 2 or better had been reached in six (75%) patients at the last visit. The steroid dosage decreased from 60 mg at baseline to 15 mg at the last follow-up (p = 0.011). The average MG-ADL score decreased from 11 (range 7 to 15) to 0 (range 0 to 3; p = 0.011), and the MMS improved from 38.5 (range 24 to 60) to 100 (range 90 to 100; p = 0.012). These differences were all statistically significant. During RTX treatment and subsequent follow-up, 1 patient reported minor post-infusion malaise. Conclusion: Low-dose RTX is effective and safe for treating anti-MuSK antibody positive MG patients. A long-term response is observed after treatment. Larger prospective studies are required to provide further evidence. Keywords: myasthenia gravis, rituximab, low-dose, muscle-specific kinase Myasthenia gravis (MG) is an acquired autoimmune disease of the postsynaptic neuromuscular junction characterized by fluctuating muscle weakness and fatigue that can involve any of the skeletal muscles. 1 The pathogenic antibodies that have been discovered thus far include anti-acetylcholine receptor antibody (AChR), muscle-specific receptor tyrosine kinase antibody (MuSK), and low-density lipoprotein receptor-related protein 4 antibody (LRP4). 1–3 Patients with anti-MuSK-antibody-positive myasthenia gravis (MuSK-MG) account for 5 to 8% of all patients with MG. 4 Compared with patients with anti-AChR-antibody-positive, and anti-AChR- and MuSK-antibody double-negative MG, MuSK-MG patients have an earlier onset, 5 and their clinical stage and condition are more serious at the time of onset. 4,6 The mainstay of treatment for MuSK-MG is immunotherapy. MuSK-MG responds quickly and effectively to steroids, but frequent relapses occur during steroid dose reduction. 7 When a patient's condition deteriorates, high-dose prednisone combined with plasma exchange or intravenous immunoglobulin should be considered. Traditional immunosuppressants, including azathioprine, mycophenolate mofetil, tacrolimus, and cyclosporine, have been successfully administered as steroid-sparing agents to treat patients with MuSK-MG. 7,8 However, some MuSK-MG patients still do not benefit from these traditional therapies. 9 Although early clinical remission can be achieved in patients after receiving standard treatments, these patients are more likely to relapse than anti-AChR MG (AChR-MG) patients, which seriously affects their quality of life. Rituximab (RTX) is a human-mouse chimeric monoclonal antibody that specifically binds to the CD20 antigen, which is expressed on the surface of 95% of B lymphoma cells and normal B lymphocytes. 10 RTX, as a drug that can deplete B cells and their precursor cells, was initially approved to treat non-Hodgkin's lymphoma. 11 However, the administration of RTX has g -Abstract Truncated-
psychiatry,clinical neurology